Ganoderma tsugae Extract Inhibits Growth of HER2-Overexpressing Cancer Cells via Modulation of HER2/PI3K/Akt Signaling Pathway

被引:17
|
作者
Kuo, Han-Peng [1 ]
Hsu, Shih-Chung [2 ]
Ou, Chien-Chih [3 ]
Li, Jhy-Wei [4 ]
Tseng, Hsiu-Hsueh [5 ]
Chuang, Tzu-Chao [6 ]
Liu, Jah-Yao [7 ]
Chen, Shih-Jung [8 ]
Su, Muh-Hwan [9 ]
Cheng, Yung-Chi [10 ]
Chou, Wei-Yuan [11 ]
Kao, Ming-Ching [1 ,11 ]
机构
[1] China Med Univ, Dept Biol Sci & Technol, Coll Life Sci, Taichung 40402, Taiwan
[2] Kang Ning Jr Coll Med Care & Management, Taipei 11486, Taiwan
[3] SynCore Bio, Oncol New Drug Div, Taipei 11070, Taiwan
[4] Da Chien Gen Hosp, Dept Pathol, Miaoli 36052, Taiwan
[5] Natl Def Med Ctr, Grad Inst Life Sci, Taipei 11490, Taiwan
[6] Tamkang Univ, Dept Chem, Tamsui 25137, New Taipei, Taiwan
[7] Triserv Gen Hosp, Dept Obstet & Gynecol, Taipei 11490, Taiwan
[8] Luo Gui Ying Fungi Agr Farm, Tao Yuan 33043, Taiwan
[9] Sinphar Grp, Sinphar Grp Headquarter, Yilan 26944, Taiwan
[10] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA
[11] Natl Def Med Ctr, Dept Biochem, Taipei 11490, Taiwan
关键词
DOWN-REGULATION; OVARIAN-CANCER; RECEPTOR; OVEREXPRESSION; HER2/NEU; CYCLE; CYTOTOXICITY; EXPRESSION; BERBERINE; ANTITUMOR;
D O I
10.1155/2013/219472
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Ganoderma, also known as Lingzhi or Reishi, has been used for medicinal purposes in Asian countries for centuries. It is a medicinal fungus with a variety of biological properties including immunomodulatory and antitumor activities. In this study, we investigated the molecular mechanisms by which Ganoderma tsugae (GT), one of the most common species of Ganoderma, inhibits the proliferation of HER2-overexpressing cancer cells. Here, we show that a quality assured extract of GT (GTE) inhibited the growth of HER2-overexpressing cancer cells in vitro and in vivo and enhanced the growth-inhibitory effect of antitumor drugs (e. g., taxol and cisplatin) in these cells. We also demonstrate that GTE induced cell cycle arrest by interfering with the HER2/PI3K/Akt signaling pathway. Furthermore, GTE curtailed the expression of the HER2 protein by modulating the transcriptional activity of the HER2 gene and the stability/degradation of the HER2 protein. In conclusion, this study suggests that GTE may be a useful adjuvant therapeutic agent in the treatment of cancer cells that highly express HER2.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Growth Suppression of HER2-Overexpressing Breast Cancer Cells by Berberine via Modulation of the HER2/PI3K/Akt Signaling Pathway
    Kuo, Han-Peng
    Chuang, Tzu-Chao
    Yeh, Ming-Han
    Hsu, Shih-Chung
    Way, Tzong-Der
    Chen, Po-Yuan
    Wang, Shan-Shue
    Chang, Yung-Hsien
    Kao, Ming-Ching
    Liu, Jah-Yao
    JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2011, 59 (15) : 8216 - 8224
  • [2] Demethoxycurcumin induces apoptosis in HER2 overexpressing bladder cancer cells through degradation of HER2 and inhibiting the PI3K/Akt pathway
    Kao, Chien-Chang
    Cheng, Yi-Ching
    Yang, Ming-Hsin
    Cha, Tai-Lung
    Sun, Guang-Huan
    Ho, Chi-Tang
    Lin, Ying-Chao
    Wang, Hao-Kuang
    Wu, Sheng-Tang
    Way, Tzong-Der
    ENVIRONMENTAL TOXICOLOGY, 2021, 36 (11) : 2186 - 2195
  • [3] Calorie restriction reduces PI3K/Akt signaling and tumorigenic potential in HER2-overexpressing breast cancer
    Smith, Laura A.
    Rainey, Magdalena A.
    Sheth, Nishita T.
    O'Flanagan, Ciara H.
    Bowers, Laura W.
    Hursting, Stephen D.
    CANCER RESEARCH, 2018, 78 (13)
  • [4] HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review
    Pan, Linghui
    Li, Jinling
    Xu, Qi
    Gao, Zili
    Yang, Mao
    Wu, Xiaoping
    Li, Xuesen
    MEDICINE, 2024, 103 (24) : e38508
  • [5] PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
    Serra, V.
    Scaltriti, M.
    Prudkin, L.
    Eichhorn, P. J. A.
    Ibrahim, Y. H.
    Chandarlapaty, S.
    Markman, B.
    Rodriguez, O.
    Guzman, M.
    Rodriguez, S.
    Gili, M.
    Russillo, M.
    Parra, J. L.
    Singh, S.
    Arribas, J.
    Rosen, N.
    Baselga, J.
    ONCOGENE, 2011, 30 (22) : 2547 - 2557
  • [6] PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
    V Serra
    M Scaltriti
    L Prudkin
    P J A Eichhorn
    Y H Ibrahim
    S Chandarlapaty
    B Markman
    O Rodriguez
    M Guzman
    S Rodriguez
    M Gili
    M Russillo
    J L Parra
    S Singh
    J Arribas
    N Rosen
    J Baselga
    Oncogene, 2011, 30 : 2547 - 2557
  • [7] A Mechanistic Logic for Dual Targeting of HER2 and PI3K/AKT/mTOR Signaling in HER2 Amplified Breast Cancer
    Chandarlapaty, S.
    Rodrik-Outmezguine, V.
    Scaltriti, M. Maurizio
    Sakr, R.
    Will, M.
    Giri, D.
    Hudis, C.
    Baselga, J.
    King, T.
    Rosen, N.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 127 - 127
  • [8] HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3
    Ruiz-Saenz, Ana
    Dreyer, Courtney
    Campbell, Marcia R.
    Steri, Veronica
    Gulizia, Nate
    Moasser, Mark M.
    CANCER RESEARCH, 2018, 78 (13) : 3645 - 3658
  • [9] HER2 down-modulation increases sensitivity to trastuzumab in HER2-overexpressing breast cancer cells
    Valabrega, Giorgio
    Montemurro, Filippo
    Aglietta, Massimo
    Giordano, Silvia
    ANNALS OF ONCOLOGY, 2005, 16 : 30 - 30
  • [10] The role of Her2 and other oncogenes of the PI3K/AKT pathway in mitochondria
    Rohlenova, Katerina
    Neuzil, Jiri
    Rohlena, Jakub
    BIOLOGICAL CHEMISTRY, 2016, 397 (07) : 607 - 615